KPI data tables

Lonza operating metrics behind the KPI charts, newest period first (up to 24 periods per chart). Periods use each company's own fiscal labels where the source does; each table names its source.

Lonza CDMO CapEx by Platform (Half-Year, Continuing) (CHF billions)
PeriodIntegrated BiologicsAdvanced SynthesisSpecialized Modalities
H1 20260.2310.1530.094
H2 20250.2270.160.176
H1 20250.2240.1450.182

Source: Lonza Half-Year Report 2026 Note 3 (22 Jul 2026) https://www.lonza.com/-/media/39523D97F3B24D6C9664FB75A9555D00. H1 2026 CapEx Integrated Biologics 231 / Advanced Synthesis 153 / Specialized Modalities 94 / Corporate 52 / continuing 530. H1 2025 restated 224 / 145 / 182 / 91 / 642. Full-Year Report 2025 Note 3 https://www.lonza.com/-/media/Lonza/Lonzacom/investor-relations/Financial%20Reports/29012026_full_year_report. FY 2025 451 / 305 / 358 / 163 / continuing 1,277. FY 2024 restated 607 / 274 / 262 / 178 / continuing 1,321. H1 2026 presentation CapEx as % of sales https://www.lonza.com/-/media/DCE06B022C6E44BBA556AC1BF49FA248.

Lonza CDMO Platform Sales (Annual, Continuing) (CHF billions)
PeriodIntegrated BiologicsAdvanced SynthesisSpecialized Modalities
FY 20253.6491.6111.034
FY 20242.8831.3231.099

Source: Lonza Full-Year Report 2025, unaudited condensed financials and Note 3 Operating Segments (28 Jan 2026), https://www.lonza.com/-/media/Lonza/Lonzacom/investor-relations/Financial%20Reports/29012026_full_year_report. FY 2025 third-party sales Integrated Biologics 3,649 / Advanced Synthesis 1,611 / Specialized Modalities 1,034. FY 2024 restated 2,883 / 1,323 / 1,099. Continuing business 6,531 and 5,480. Vacaville around CHF 0.6 billion in the Integrated Biologics narrative. FY 2025 news release https://www.lonza.com/news/2026-01-28-06-30. Reporting Center https://www.lonza.com/investor-relations/reporting-center.

Lonza CDMO Platform Sales (Half-Year, Continuing) (CHF billions)
PeriodIntegrated BiologicsAdvanced SynthesisSpecialized Modalities
H1 20261.870.8340.553
H2 20251.8360.9550.56
H1 20251.8130.6560.474

Source: Lonza Half-Year Report 2026, Note 3 Operating Segments (22 Jul 2026), https://www.lonza.com/-/media/39523D97F3B24D6C9664FB75A9555D00. H1 2026 third-party sales Integrated Biologics 1,870 / Advanced Synthesis 834 / Specialized Modalities 553. H1 2025 restated 1,813 / 656 / 474 (Advanced Synthesis restated after a site moved to CHI). Continuing sales 3,374 and 3,034. FY 2025 platform totals from Full-Year Report 2025 https://www.lonza.com/-/media/Lonza/Lonzacom/investor-relations/Financial%20Reports/29012026_full_year_report. H2 2025 group print of 3,500 in Full-Year Results 2025 presentation https://cdn.prod.nntech.io/company-events/reports/7f38f3bf-4e2f-39c4-9db0-1112836fb87b/presentation.pdf. H1 2026 news https://www.lonza.com/news/2026-07-22-06-30.

Ask Sterling

Register for a premium account to gain access to Sterling AI.

Get Started

Things you can ask Sterling:

Summarize Tesla's latest earnings reportWhy did NVIDIA's margins expand?Compare Apple vs Microsoft's cash flowWhat's driving EV industry growth?
Menu
Favorites
Lonza (LONN.SW) - KPIs | Sterling